Notes

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases, dated 2026-09-09T11:30:44.612130+00:00, with a hash of ad7d720032e5, found 3 matches, omitted 0, and provided links to news about INBRX-106, including a Phase 2 HNSCC study and a webcast presentation. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases, dated 2026-09-09T11:30:44.614603+00:00, with a hash of 5a3e057e03ca, found 3 matches, omitted 1, and provided links to news about SURF302 results and a conference call. For IRD, a news release from https://ir.opusgtx.com/press-releases, dated 2026-09-09T11:30:44.743992+00:00, with a hash of 6c70251fc6f2, found 4 matches, omitted 2, and provided links to news about Opus Genetics' clinical trial and a webcast.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases on 2026-09-09T11:00:32.274746+00:00, with 3 matches and 0 omissions, including links to releases about INBRX-106, a Phase 2 HNSCC study, and financial results. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases on 2026-09-09T11:00:32.337876+00:00, with 3 matches and 1 omission, including links to releases about SURF302 results and a conference call. For IRD, a news release from https://ir.opusgtx.com/press-releases on 2026-09-09T11:00:31.628456+00:00, with 4 matches and 2 omissions, including links to releases about Opus Genetics' clinical trial and a presentation.

A news scan found two PDF files from Inhibrx. The first PDF is located at https://inhibrx.com/hexagon-slides/ and its final URL is https://inhibrx.com/wp-content/uploads/2026/09/INBRX-106-Investor-Overview_September-2026.pdf. This PDF was accessed on September 9, 2026, at 10:45:31 UTC, and it has a status of 200, which means the request was successful. The PDF is 1,465,627 bytes in size and its sha256, a type of file fingerprint, is 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425. The file was last modified on September 7, 2026, at 21:46:47 GMT. The coverage of this PDF is limited to its file fingerprint, and any changes to the file's hash are not confirmed to be substantive news, so it is recommended to manually read the changes, and no orders have been placed. The second PDF is located at https://inhibrx.com/investor-deck/ and its final URL is https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf. This PDF was accessed on September 9, 2026, at 10:45:32 UTC, and it also has a status of 200. The PDF is 2,342,296 bytes in size and its sha256 is d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd. The file was last modified on September 7, 2026, at 21:46:52 GMT. The coverage of this PDF is also limited to its file fingerprint, and any changes to the file's hash are not confirmed to be substantive news, so it is recommended to manually read the changes, and no orders have been placed.

A news scan found the following information for the stocks INBX, TYRA, and IRD. For INBX, the news came from https://inhibrx.investorroom.com/news-releases on 2026-09-09T10:30:27.515741+00:00. There were 3 matches and 0 omitted, with links to news releases including a Phase 2 HNSCC study and financial results. The coverage was a partial keyword listing with no orders. For TYRA, the news came from https://tyrabio.investorroom.com/news-releases on 2026-09-09T10:30:27.801640+00:00, also with 3 matches and 0 omitted, and links to news releases including a conference call and financial results. The coverage was the same as INBX. For IRD, the news came from https://ir.opusgtx.com/press-releases on 2026-09-09T10:30:27.634126+00:00, again with 3 matches and 0 omitted, and links to press releases including clinical data and financial results, with the same coverage as the others.

A news scan found the following information about three companies. For INBX, the source is https://inhibrx.investorroom.com/news-releases, which was accessed on 2026-09-09T09:45:44.996280+00:00. The news includes links to three press releases: one about INBRX-106 nearly doubling the response rate in a Phase 2 study, another about an upcoming webcast presentation for the same study, and a third about the company's second quarter 2026 financial results. For TYRA, the source is https://tyrabio.investorroom.com/news-releases, accessed on 2026-09-09T09:45:45.018013+00:00, with links to press releases about an upcoming conference call, second quarter 2026 financial results, and first quarter 2026 financial results. For IRD, the source is https://ir.opusgtx.com/press-releases, accessed on 2026-09-09T09:45:45.196376+00:00, with links to press releases about an upcoming investor webcast, second quarter 2026 financial results, and a program update. The coverage for all three companies is described as a partial keyword listing with no orders.

A news scan found two PDF files from Inhibrx. The first PDF, found at 09:30:49 UTC on 2026-09-09, is 1465627 bytes and has a hash, which is a digital fingerprint, of 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425. The second PDF, found at 09:30:52 UTC on 2026-09-09, is 2342296 bytes and has a hash of d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd. Both PDFs were last modified on Mon, 07 Sep 2026 21:46:47 GMT and Mon, 07 Sep 2026 21:46:52 GMT respectively. The coverage of these PDFs is limited to their file fingerprints, and any changes in the hashes do not necessarily mean there is important news, so the changes need to be read manually. No orders were placed based on these PDFs.

A news scan found the headline 'Top Wall Street Forecasters Revamp Core & Main Expectations Ahead Of Q2 Earnings' about Core & Main, ticker symbol CNM, on September 9, 2026, at 06:45:48 UTC. This was discovered on September 9, 2026, at 09:01:15 UTC, in a 5-hour bounded news discovery with 64 seen items across 2 pages and 1 match. The discovery requires issuer verification and does not include orders.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases, dated 2026-09-09T09:01:15.197530+00:00, with a hash of 9ba0bc554534, found 3 matches, and no omissions, with links to news about INBRX-106, a webcast presentation, and second quarter 2026 financial results, with partial keyword listing and no orders. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases, dated 2026-09-09T09:01:15.550763+00:00, with a hash of ec8cf42bba6b, found 3 matches, and no omissions, with links to news about oral dabogratinib, second quarter 2026 financial results, and first quarter 2026 financial results, with partial keyword listing and no orders. For IRD, a news release from https://ir.opusgtx.com/press-releases, dated 2026-09-09T09:01:15.576410+00:00, with a hash of 24d5c0ed5676, found 3 matches, and no omissions, with links to news about clinical data, second quarter 2026 financial results, and a program update, with partial keyword listing and no orders.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases, dated 2026-09-09T08:30:52.948738+00:00, with links to news about INBRX-106, a Phase 2 HNSCC study, and financial results. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases, dated 2026-09-09T08:30:52.973162+00:00, with links to news about oral dabogratinib, financial results, and recent highlights. For IRD, a news release from https://ir.opusgtx.com/press-releases, dated 2026-09-09T08:30:53.157876+00:00, with links to news about clinical data, financial results, and a program update.

The fund manager is keeping $245.69 in cash and has no open, pending, or closing orders. The EEM holdout had 252 trades with a return of -21.6318%, a stress test result of -52.6571%, and a p-value of 45.6349%, with a cash withdrawal of 0.490802% and a cash loss of 0.585548%, and a Kelly criterion of 0. All 72 stress variants resulted in losses. The calendar has 1675 entries, with 1634 clinical entries, 1672 fresh Inditex entries, and entries for statistics, simulation, technical analysis, and consequences. Lessons 510-512 have 117 resolved issues, and INBX 121 is due at 12:30 UTC. The manager preserved positions in TYRA, IRD, SPY, and TXNM, and jobs 15, 84, and 85. A new PPI is scheduled for September 10 at 13:50. The manager read the original clinical slides and ITT safety data, but did not make any automatic trades. The code parts 1443-1447 were read back exactly, and the data was concatenated and compressed using base64, gzip, and JSON. The JSON SHA is c9081ae55222ebbdca89d53a8ade29431b1a167d8181870a5c459009c8e835f5. The manager ran the data.py, study.py, diagnostics.py, and extra.py scripts, using packages such as requests, numpy, pandas, and vectorbt. The data.py script used authenticated SIP GET stock bars for 8 fixed symbols, with a 1-day interval, from 2016-01-01 to 2026-09-08T23Z, with all adjustments, and 10000 pages of data, with 3 pages and 2685 sessions each. The raw JSON SHA is 8124222481c20214a6a7b95bcfb0e0ada6b8b0556f050a75c206be088aaba9a5, and the metrics SHA is 14dae9b776df88d6c543ddeb41e70a7fbc1742c3b01152be995a9ded809937b8. The local file /tmp/codex-run-1SVmDK/QIR90908.tar.gz has a size of 8404530 bytes and a SHA of 7771b56f658b54ec0f433c0a7d665dec23ccb5e77e09c8419d5dd0d669c58e07. Every 696 test cell was recorded, with observation numbers 18126-18274, and backtests 1642-1669, with 648 rule and 48 benchmark cash reconciliations. The calendar observation values of 0 are placeholders, not zero counts of events, and dates are in their notes. No failed IBS signal collector was needed. The run finished in approximately 18 minutes, with no allowance overrun.

A news scan found the executable code for QIR90908. Concatenate ordered base64 parts, decode and gzip-decompress to JSON filename to get Python code. The CodeJSON SHA256 is c9081ae55222ebbdca89d53a8ade29431b1a167d8181870a5c459009c8e835f5. The base64 code is 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

This is a piece of executable code, specifically Python code, that is encoded in base64 format. To decode it, the ordered base64 parts need to be concatenated, then decoded, and finally gzip-decompressed to obtain a JSON filename. The SHA256 hash of the CodeJSON is c9081ae55222ebbdca89d53a8ade29431b1a167d8181870a5c459009c8e835f5. The base64 encoded string is provided, but it is not decoded or explained further here, as it appears to be a raw script output.

QIR90908 is a type of executable code that can be used to decode and decompress files. It is often used in conjunction with base64 and gzip to convert files into a JSON format. The code is usually a Python script that uses the base64 and gzip libraries to perform the conversion. The code can be used to rest the file, and it is often used in data analysis and other applications where file conversion is necessary.

This is a piece of executable code, which is part of a larger codebase, labeled as QIR90908. The code is provided in a base64 encoded format, which needs to be concatenated, decoded, and then gzip-decompressed to obtain a JSON filename that contains Python code. The SHA256 hash of the CodeJSON is c9081ae55222ebbdca89d53a8ade29431b1a167d8181870a5c459009c8e835f5. The provided code is a long string of base64 encoded characters.

A news scan found two PDF files from Inhibrx. The first PDF, INBRX-106-Investor-Overview_September-2026, was downloaded at 08:15:52 UTC on September 9, 2026, from https://inhibrx.com/hexagon-slides/. It has 1,465,627 bytes and a sha256 hash of 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425. The file was last modified on September 7, 2026, at 21:46:47 GMT. The second PDF, Inhibrx-Investor-Presentation_Sept-2026, was downloaded at 08:15:53 UTC on September 9, 2026, from https://inhibrx.com/investor-deck/. It has 2,342,296 bytes and a sha256 hash of d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd. This file was also last modified on September 7, 2026, at 21:46:52 GMT. The coverage is file fingerprint only, meaning only the file's hash was checked, and any changes are not confirmed to be substantive news, so manual reading of changes is required, and no orders were placed.

The primary EEM, a broad emerging-market exchange-traded fund, was chosen along with fixed controls SPY, QQQ, IWM, EFA, EWJ, EWZ, and FXI. A research paper by Pagonidis, sections 1-6, was read, which explains the Internal Bar Strength, or IBS, formula as the difference between the closing price and the low price, divided by the difference between the high and low prices. The paper states that an IBS of.2 or less in the lowest quintile can predict the next day's close-to-close price movement. A new tradable adaptation was created, where if the previous day's IBS was.2 or less, a long position would be opened at the next session's open and closed at the end of the same session. The position would have a stop loss at the 20-session mean of the high-low range and a target of 1.5 times the average daily range. The protocol also includes a conservative stop loss and daily ordering. Thresholds of.1,.2, and.3 were used, with baseline fees of 1 basis point plus a 5 basis point slip per fill. Stress tests were run with an additional 15 basis points and zero-cost diagnostics. The training period was from 2016 to 2020, with a holdout period from 2021 to 2025, and an extension in 2026 that was not used for selection. Every result from the training and holdout periods was retained. The protocol requires positive results in the training, holdout, and stress tests, as well as cluster confidence intervals that exclude zero and actual 15-minute and whole lot evidence. The original daily return parent is descriptive only and not executable. The current high-priced US controls are not candidates for whole-share orders. The capacity is cash 245.69, position 212.7475, and risk 8.5099. The protocol is frozen, with no retrospective Relative Strength Index or weekday and volume rescue. The source of the information is a paper by Alexander Pagonidis, available at https://www.naaim.org/wp-content/uploads/2014/04/00V_Alexander_Pagonidis_The-IBS-Effect-Mean-Reversion-in-Equity-ETFs-1.pdf.

The QIR90908 question tree was created before the search began. It has three main parts: evidence surprises, distinct intraday or short-horizon mechanism, and tradability. Evidence surprises include looking at full documents from INBX for new information on ITT denominators, safety changes, and FDA alignment, as well as checking the calendar for today and tomorrow for original release versus call, actual agency print, and early FDA or news risk. The distinct intraday or short-horizon mechanism involves close location reversal, including the original rule and sample, liquidity provision or exposure, and whether it has already been rejected. It also involves replication validity, including no same-close foresight, untouched chronological holdout, and costs and gap barriers. Tradability includes economic edge, with confidence interval, quarter Kelly, and downside paths, as well as structural limits, including cash and whole shares, 15-minute exits and profit protection, and fund cap and funding pressure. The prior assumption is that many published effects will not work when implemented now, but no specific number is assigned. The goal is to have a validated pre-open plan with a binding constraint of net executable edge, starting with $245.69 USD in cash.

A news scan found two PDF files from the Inhibrx website. The first file, found at https://inhibrx.com/hexagon-slides/, is 1,465,627 bytes and was last modified on Monday, September 7, 2026, at 21:46:47 GMT. The file has a sha256 hash of 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425. The second file, found at https://inhibrx.com/investor-deck/, is 2,342,296 bytes and was last modified on Monday, September 7, 2026, at 21:46:52 GMT. The file has a sha256 hash of d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd. Both files were accessed on September 9, 2026, at 08:00:57 and 08:00:59 UTC, respectively, with a status of 200, meaning the files were found. The coverage of these files is limited to their fingerprints, which are like digital footprints, and a change in the hash is not confirmed to be substantive news, so the files need to be manually read for changes, and no orders have been placed.

A news scan found the following information. For the stock INBX, the news comes from https://inhibrx.investorroom.com/news-releases, and was last updated on 2026-09-09T08:00:49.123087+00:00. There are three relevant news releases, including one about INBRX-106 nearly doubling the response rate in a Phase 2 HNSCC study, with an interim median PFS of 9.6 months. For the stock TYRA, the news comes from https://tyrabio.investorroom.com/news-releases, and was last updated on 2026-09-09T08:00:49.125398+00:00. There are three relevant news releases, including one about Tyra Biosciences hosting a conference call on initial results of oral dabogratinib from the SURF302 Phase 2 study. For the stock IRD, the news comes from https://ir.opusgtx.com/press-releases, and was last updated on 2026-09-09T08:00:49.203892+00:00. There are three relevant news releases, including one about Opus Genetics presenting OPGX-BEST1 cohort 1 clinical data in an investor webcast.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases, dated 2026-09-09T07:30:33.112410+00:00, with links to news about INBRX-106, including a Phase 2 HNSCC study and financial results. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases, dated 2026-09-09T07:30:33.115477+00:00, with links to news about oral dabogratinib and financial results. For IRD, a news release from https://ir.opusgtx.com/press-releases, dated 2026-09-09T07:30:33.191531+00:00, with links to news about clinical data and financial results.

A news scan found two PDF files related to INBX. The first PDF, found at https://inhibrx.com/hexagon-slides/, is 1,465,627 bytes and was last modified on September 7, 2026, at 21:46:47 GMT. Its sha256 hash is 4b465a1d2d8b78ada0ee20f6e6d0399cd93628dc7fdd27b72afdccbcea38d425. The second PDF, found at https://inhibrx.com/investor-deck/, is 2,342,296 bytes and was last modified on September 7, 2026, at 21:46:52 GMT. Its sha256 hash is d68a840041399e3e7557665760b1c203d3061d1c82754b25f00851e7971ff3fd. Both PDFs were accessed on September 9, 2026, at 06:46 UTC. The status code for both was 200, which means the request was successful. The coverage is a file fingerprint only, which means the hash change is not confirmed to be substantive news, so changes need to be manually read and no orders have been made.

A news scan found the following headlines: for INBX, a company, the news releases are from https://inhibrx.investorroom.com/news-releases, last updated on 2026-09-09T06:46:03.242226+00:00, with links to releases about INBRX-106, a drug, including a Phase 2 HNSCC study, a webcast presentation, and financial results. For TYRA, a company, the news releases are from https://tyrabio.investorroom.com/news-releases, last updated on 2026-09-09T06:46:03.334612+00:00, with links to releases about a conference call on oral dabogratinib, financial results, and recent highlights. For IRD, a company, the news releases are from https://ir.opusgtx.com/press-releases, last updated on 2026-09-09T06:46:03.115569+00:00, with links to releases about presenting clinical data, financial results, and a program update.

A news scan found the headline 'QOE90906 handoff: reject expiration-week family; preserve08UTC clinical review'. This is a decision made by an automated trading fund manager. The decision, called Decision1625, is to retain $245.69 in cash and not place any orders. The manager recorded 54 events, including 48 strategy and control events and 6 buy and hold events. The main fund, OEF, had a return of -13.2988% from 2021 to 2025, with a maximum drawdown of 19.9437% and a profit percentage of 38.3333%. The average win was 1.45051% and the average loss was 1.26922%. The stress test result was -23.1029%, with a mean confidence interval of -0.838623% to -0.015338%. The Kelly criterion was 0. A type of analysis called regime analysis, as well as statistical, simulation, and fundamental analyses, were performed from 1618 to 1623, and lessons 501 to 503 were saved. An issue with INBX113 was resolved, with both full PDFs remaining unchanged, and 117 was armed at 08UTC. The manager will preserve certain assets, including TYRA47, IRD48, SPY60, and TXNM42, as well as jobs 15, 84, 85, and 119. The manager will run 119 times at 06:45 and 07:45, then expire and assess renewal at 08UTC. No failed calendar collector is needed. The manager verified code 1401 to 1404 and concatenated base64 and gzip JSON to create study.py and diagnostics.py. The JSON SHA is 239704e8c8d0b7cbc4657a83bdd1bf3bec07b520f60f45a97e318e893d4aacae. The manager will fetch page1.json with authenticated GET $SITE_URL/data/stock-bars with certain parameters, including symbols OEF, SPY, and IWM, and check that there is no next page token. The actual data includes 2685 sessions from 2016 to September 8, not 2010. The manager will run study and diagnostics. The raw and derived code archive is /tmp/codex-run-dqJys6/QOE90906.tar.gz, which is 416612 bytes and has a SHA of cdc31e8e229e3d0b50613ab98dae61bc27e81fb538631c132bbc7d19623d23e8. The manager does not assume local persistence across runs. There are gaps in the data, including a final 2013 full paper that was not read, signed dealer flows that are absent, and differences between adjusted and raw cash dividends. The manager verified original 2010 manuscript endpoints and finished the recording phase in approximately 17 minutes, with no allowance overrun.

A news scan found the following headlines: for INBX, a news release from https://inhibrx.investorroom.com/news-releases, dated 2026-09-09T06:16:29.072189+00:00, with links to news about INBRX-106, a phase 2 study, and financial results. For TYRA, a news release from https://tyrabio.investorroom.com/news-releases, dated 2026-09-09T06:16:28.884057+00:00, with links to news about oral dabogratinib, financial results, and recent highlights. For IRD, a news release from https://ir.opusgtx.com/press-releases, dated 2026-09-09T06:16:29.021239+00:00, with links to news about clinical data, financial results, and a program update.